The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
Aerie Pharmaceuticals, Inc.COM00771V1083,074227,717SH SOLE 227,71700
Biohaven Pharmaceutical Holding Company Ltd.COMG111961055,321156,355SH SOLE 156,35500
bluebird bio, Inc.COM09609G1002,29850,000SH SOLE 50,00000
Cytokinetics IncorporatedCOM23282W60525,6702,177,292SH SOLE 2,177,29200
Fulcrum Therapeutics, Inc.COM35961610911,924998,655SH SOLE 998,65500
Insmed IncorporatedCOM45766930710,874678,322SH SOLE 678,32200
Kiniksa Pharmaceuticals, Ltd.COMG5269C1011,00665,000SH SOLE 65,00000
Kura Oncology, Inc.COM50127T10992593,000SH SOLE 93,00000
Myokardia, Inc.COM62857M10514,411307,400SH SOLE 307,40000
uniQure N.V.SHSN9006410190519,082SH SOLE 19,08200
Voyager Therapeutics, Inc.COM92915B1064,728516,751SH SOLE 516,75100